3 unknown, 2 not yet recruiting, 1 terminated. 3 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 2, Terminated 1 |
| Phase 1 | 2 | Terminated 1, Unknown 1 |
| Phase 3 | 2 | Not yet recruiting 2 |
Follow JMT103: new trials by email Literature Review of JMT103 trials Research Report on JMT103
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid JMT103, zoledronic acid - Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors | Phase 3 | Not yet recruiting | Shanghai JMT-Bio Inc. | 1360 | 2024-04-05 | 2024-01-24 |
| A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone Narlumosbart, Denosumab - Giant Cell Tumor of Bone | Phase 3 | Not yet recruiting | Shanghai JMT-Bio Inc. | 146 | 2023-04-01 | 2023-04-19 |
| Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis JMT103, Alendronate sodium, JMT103 placebo - Glucocorticoid Induced Osteoporosis | Phase 2 | Unknown | Shanghai JMT-Bio Inc. | 231 | 2022-06-15 | 2022-05-31 |
| Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis JMT103, Denosumab, Placebo - Postmenopausal Osteoporosis | Phase 2 | Unknown | Shanghai JMT-Bio Inc. | 200 | 2022-04-21 | 2022-07-18 |
| A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM JMT103 - Hypercalcemia of Malignancy | Phase 1 / Phase 2 | Terminated | Shanghai JMT-Bio Inc. | 4 | 2020-04-22 | 2026-09-18 |
| Safety, Tolerability and PK/PD of JMT103 in Patients With Bone Metastases From Tumors Anti-RANKL Monoclonal Antibody - Bone Metastases | Phase 1 | Unknown | Shanghai JMT-Bio Inc. | 36 | 2018-05-21 | 2018-06-08 |
Giant Cell Tumor of Bone (1) · Humoral Hypercalcemia Of Malignancy (1) · Osteoporosis, Postmenopausal (1)
China (5)
Jin LI, PHD (1) · Jin Li, MD (1) · Weibo Xia (1) · Xiaohui Niu, B.M. (1)